Yutrepia™ (treprostinil) – New drug approval

- On May 23, 2025, Liquidia Corporation announced the FDA approval of Yutrepia (treprostinil) inhalation powder, for the **treatment of:**
  - Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
  - Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
- **Treprostinil is currently available via several other formulations, including United Therapeutics' inhalation powder** (Tyvaso DPI®).
- Warnings and precautions for Yutrepia include risk of symptomatic hypotension, risk of bleeding, effect of other drugs on treprostinil, and bronchospasm.
- The most common adverse reactions (≥ 10%) with Yutrepia use were cough, headache, throat irritation, and dizziness.
- Refer to the Yutrepia label for complete dosing and administration recommendations.
- United Therapeutics filed a complaint in a U.S. District Court against Liquidia on May 9, 2025, alleging patent infringement. United Therapeutics has filed a motion for temporary restraining order and preliminary injunction to block Liquidia from commercially launching Yutrepia. The motion remains pending with the Court.
- Yutrepia will be available as an inhalation powder contained in capsules (26.5 mcg, 53 mcg, 79.5 mcg, and 106 mcg).